Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jinxi Ding"'
Autor:
Haoye Li, Fanyu Lin, Rui Wang, Chenxuan Zhu, Keyao Cao, Yu Chen, Gang Fang, Jiaming Li, Jinxi Ding, Wei Li
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Purpose Under the background of the regular implementation of the National Centralized Drug Procurement (NCDP) policy, this study aimed to assess the impacts of the NCDP policy on drug utilization of county-level medical institutions, and pr
Externí odkaz:
https://doaj.org/article/3b553f6b4e29404b9208df3b3c9d91f1
Publikováno v:
International Journal for Equity in Health, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Background China has implemented policies to make rare diseases more affordable. While previous studies evaluated overall affordability, few have examined affordability differences across regions and disease types. Given the vastness of Chin
Externí odkaz:
https://doaj.org/article/f901866998574473abf8bdd9d874653f
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectiveThis study aimed to evaluate the impact of the National Centralized Drug Procurement (NCDP) policy on chemical pharmaceutical enterprises’ R&D investment and provide references for improving NCDP policy design and encouraging innovation in
Externí odkaz:
https://doaj.org/article/b8790c558448420ca71abb2e87ee3d37
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveThis study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China.Materials and methodsCancer drugs marketed before June 30th, 2021 with publicly ava
Externí odkaz:
https://doaj.org/article/cd035a5f6a644a66b381a43e668a1cdc
Publikováno v:
Journal of Technology Management & Innovation, Vol 6, Iss 2 (2011)
Research & Development (R&D) plays an increasingly important role in China’s pharmaceutical industry. To gain a competitive edge in the global pharmaceutical market, the current national strategy of China forcefully pushes for independent drug inno
Externí odkaz:
https://doaj.org/article/c49ab430e0f34d358d79e8600934a18e
Autor:
Jinxi Ding
Publikováno v:
Journal of World Architecture. 5:5-8
Currently, expressways encourage the use of interchange design methods in the layout mode to improve the safety of expressway operation in order to relieve road transportation pressure and strengthen the prevention of traffic safety accidents. The ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15147a5bc3f8e431b42c85536a2c44b8
https://doi.org/10.26689/jwa.v5i3.2175
https://doi.org/10.26689/jwa.v5i3.2175
Publikováno v:
Pharmacology & Pharmacy. 12:247-254
Objective: To put forward suggestions to improve the linkage mechanism between China’s essential medicine list and healthcare insurance medicine list. Methods: Comparative study of the organization setting, selection criteria, adjustment procedures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63b57353f9acd6137ee4d27832c35f5b
https://doi.org/10.4236/pp.2021.1211021
https://doi.org/10.4236/pp.2021.1211021
Autor:
Jinxi Ding
Publikováno v:
Journal of Architectural Research and Development. 5
Highway is an important kind of infrastructure which the transportation sector depends on. The rationality of the interchange design between urban roads and expressways is related to the relieving of urban traffic pressure. Based on the status quo of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd84d05a62ceefe631b216641b53ab1d
https://doi.org/10.26689/jard.v5i3.2168
https://doi.org/10.26689/jard.v5i3.2168
Publikováno v:
Journal of Clinical Medicine Research. 3:81
Objective — To analyze the situation of the provincial-level overall planning of basic medical insurance in China, so as to put forward some suggestions on the path of promoting the provincial-level overall planning in China. Methods — By means o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::231942b49d22a94c8d4d37bbbfa0e7d0
https://doi.org/10.32629/jcmr.v3i2.858
https://doi.org/10.32629/jcmr.v3i2.858
Publikováno v:
Clinical Therapeutics. 39:1040-1051
Purpose Our aim was to characterize the newly established new drug conditional approval process in China and discuss the challenges and opportunities with respect to new drug research and development and registration. Methods We examined the new appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::229d028c80c41f54331ed9e1d946c4ca
https://doi.org/10.1016/j.clinthera.2017.03.016
https://doi.org/10.1016/j.clinthera.2017.03.016